Palmoplantar pustulosis is a type of psoriasis, and biologics can be used in the treatment of this disease, but there are individual differences in specific efficacy. Palmoplantar pustulosis is a chronic relapsing dermatologic condition characterized by recurrent episodes of aseptic pustules on the palms of the hands and/or soles of the feet; it is most commonly seen in middle-aged and older women between the ages of 50 and 60 years; and is most often associated with smoking, stress, infections, and medications. The first-line treatments for palmoplantar pustulosis include topical glucocorticoids, oral retinoids, and photochemotherapy. Immunosuppressive drugs such as cyclosporine and methotrexate can also be used under medical supervision, with the caveat that these drugs have significant adverse effects, and patients need to use them in accordance with their doctor’s instructions. Biological agents refers to microorganisms (bacteria, rickettsiae, viruses, etc.) and their metabolites, effective antigenic components, animal toxins, human or animal blood or tissues processed as a preventive, therapeutic, diagnostic corresponding to infectious diseases or other related diseases of biological products. Its difference from traditional drugs lies in the fact that it can realize the “precision strike” on the target molecules in the body and effectively control the disease. Currently, biologics used in the treatment of psoriasis include etanercept and stavudine. They can be used in the treatment of palmoplantar pustulosis, but there are individual differences in their effectiveness. The disease can be tricky to treat. When palmoplantar pustulosis occurs, it is recommended that patients go to a regular hospital and receive treatment under the guidance of a professional doctor.